SK281095B6 - Hydroxynaftoát-4-hydroxy-alfa1-[[[6-(4- -fenylbutoxy)hexyl]amino]metyl]-1,3-benzéndimetanolu vhodný na mikronizáciu, spôsob jeho výroby, farmaceutická dávkovacia forma s jeho obsahom a jeho použitie - Google Patents

Hydroxynaftoát-4-hydroxy-alfa1-[[[6-(4- -fenylbutoxy)hexyl]amino]metyl]-1,3-benzéndimetanolu vhodný na mikronizáciu, spôsob jeho výroby, farmaceutická dávkovacia forma s jeho obsahom a jeho použitie Download PDF

Info

Publication number: SK281095B6
Authority: SK; Slovakia
Prior art keywords: organic solvent; hydroxynaphthoate; microcrystals; mixture; water
Prior art date: 1990-11-29

Application number

SK545-93A

Other languages

English (en)

Slovak (sk)

Other versions

SK54593A3 (en

Inventor

Steven Frederick Beach

David William Stuart Latham

Tony Gordon Roberts

Colin Brian Sidgwick

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-29

Filing date

1991-11-28

Publication date

2000-11-07

1991-11-28 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

1993-10-06 Publication of SK54593A3 publication Critical patent/SK54593A3/sk

2000-11-07 Publication of SK281095B6 publication Critical patent/SK281095B6/sk

Links

238000002360 preparation method Methods 0.000 title claims abstract description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims abstract 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 title claims abstract 4
238000000034 method Methods 0.000 title claims description 26
239000002552 dosage form Substances 0.000 title claims description 5
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 title abstract 2
239000003960 organic solvent Substances 0.000 claims abstract description 49
239000000203 mixture Substances 0.000 claims abstract description 37
239000002245 particle Substances 0.000 claims abstract description 24
239000013081 microcrystal Substances 0.000 claims abstract description 17
ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 claims description 55
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 54
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 claims description 7
125000005233 alkylalcohol group Chemical group 0.000 claims description 6
238000009826 distribution Methods 0.000 claims description 4
125000005907 alkyl ester group Chemical group 0.000 claims description 3
150000005215 alkyl ethers Chemical class 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
238000009835 boiling Methods 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims 7
125000003836 4-phenylbutoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims 1
FWLBHDDQPNMYJD-UHFFFAOYSA-N OC1=C(C2=CC=CC=C2C=C1)C(=O)O.C1(=CC=CC=C1)CCCCOCCCCCCNCC1(CC(=CC=C1)CO)CO Chemical compound OC1=C(C2=CC=CC=C2C=C1)C(=O)O.C1(=CC=CC=C1)CCCCOCCCCCCNCC1(CC(=CC=C1)CO)CO FWLBHDDQPNMYJD-UHFFFAOYSA-N 0.000 claims 1
229960004217 benzyl alcohol Drugs 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
-1 isopropanyl Chemical group 0.000 claims 1
239000000463 material Substances 0.000 abstract description 13
150000003839 salts Chemical class 0.000 abstract description 3
UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 abstract 1
SWPCURCTHNTSKL-UHFFFAOYSA-N C1=CC=CC2=C(O)C(C(=O)O)=CC=C21.C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21.C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 SWPCURCTHNTSKL-UHFFFAOYSA-N 0.000 abstract 1
239000002152 aqueous-organic solution Substances 0.000 abstract 1
238000010791 quenching Methods 0.000 abstract 1
230000000171 quenching effect Effects 0.000 abstract 1
229940126062 Compound A Drugs 0.000 description 43
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 43
239000002904 solvent Substances 0.000 description 11
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
230000000704 physical effect Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
239000013078 crystal Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000002425 crystallisation Methods 0.000 description 4
230000008025 crystallization Effects 0.000 description 4
238000005755 formation reaction Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 3
208000023504 respiratory system disease Diseases 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000012265 solid product Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 2
238000003889 chemical engineering Methods 0.000 description 2
239000002178 crystalline material Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
101710152983 Beta-2 adrenergic receptor Proteins 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000007561 laser diffraction method Methods 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
238000007780 powder milling Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
239000012925 reference material Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001052 transient effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
- C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Oncology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polyesters Or Polycarbonates (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Fats And Perfumes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

SK545-93A 1990-11-29 1991-11-28 Hydroxynaftoát-4-hydroxy-alfa1-[[[6-(4- -fenylbutoxy)hexyl]amino]metyl]-1,3-benzéndimetanolu vhodný na mikronizáciu, spôsob jeho výroby, farmaceutická dávkovacia forma s jeho obsahom a jeho použitie SK281095B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB909026005A GB9026005D0 (en)	1990-11-29	1990-11-29	Drug material suitable for micronisation
PCT/GB1991/002108 WO1992009557A1 (en)	1990-11-29	1991-11-28	Benzenedimethanol suitable for micronisation

Publications (2)

Publication Number	Publication Date
SK54593A3 SK54593A3 (en)	1993-10-06
SK281095B6 true SK281095B6 (sk)	2000-11-07

Family

ID=10686212

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK545-93A SK281095B6 (sk)	1990-11-29	1991-11-28	Hydroxynaftoát-4-hydroxy-alfa1-[[[6-(4- -fenylbutoxy)hexyl]amino]metyl]-1,3-benzéndimetanolu vhodný na mikronizáciu, spôsob jeho výroby, farmaceutická dávkovacia forma s jeho obsahom a jeho použitie

Country Status (27)

Country	Link
US (1)	US5380922A (cs)
EP (2)	EP0639176B1 (cs)
JP (1)	JP3375626B2 (cs)
KR (1)	KR100192196B1 (cs)
AT (1)	ATE144244T1 (cs)
AU (1)	AU644505B2 (cs)
BG (1)	BG61340B1 (cs)
CA (1)	CA2099586C (cs)
CY (1)	CY2009A (cs)
CZ (1)	CZ282996B6 (cs)
DE (1)	DE69122780T2 (cs)
DK (1)	DK0639176T3 (cs)
ES (1)	ES2093812T3 (cs)
FI (2)	FI118155B (cs)
GB (1)	GB9026005D0 (cs)
GR (1)	GR3022088T3 (cs)
HK (1)	HK78997A (cs)
HU (1)	HU218205B (cs)
IE (1)	IE914146A1 (cs)
OA (2)	OA09861A (cs)
PL (2)	PL169722B1 (cs)
RU (2)	RU2116293C1 (cs)
SG (1)	SG49741A1 (cs)
SK (1)	SK281095B6 (cs)
TW (1)	TW309425B (cs)
WO (1)	WO1992009557A1 (cs)
ZA (1)	ZA919401B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9026005D0 (en) *	1990-11-29	1991-01-16	Glaxo Group Ltd	Drug material suitable for micronisation
WO1993016031A1 (en) *	1992-02-11	1993-08-19	Glaxo Group Limited	Benzenedimethanol derivative suitable for micronisation
US6254882B1 (en)	1997-09-16	2001-07-03	Sepracor Inc.	Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
ES2193069T3 (es)	1999-04-14	2003-11-01	Glaxo Group Ltd	Formulacion farmaceutica en aerosol.
WO2002026239A1 (en)	2000-09-26	2002-04-04	Temple University Of The Commonwealth System Of Higher Education	Analgesic and glucosamine compositions
EP2127641A1 (en)	2008-05-26	2009-12-02	Inke, S.A.	Micronisable form of salmeterol xinafoate
KR101100614B1 (ko)	2010-09-20	2011-12-29	한국수력원자력 주식회사	농축폐액 건조물의 펠렛화 장치 및 방법과 이를 이용한 유리조성개발 방법
WO2016142582A1 (en)	2015-03-11	2016-09-15	Fermion Oy	Process for the preparation of crystalline salmeterol and its xinafoate salt

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZW6584A1 (en) *	1983-04-18	1985-04-17	Glaxo Group Ltd	Phenethanolamine derivatives
GB9026005D0 (en) *	1990-11-29	1991-01-16	Glaxo Group Ltd	Drug material suitable for micronisation

1990
- 1990-11-29 GB GB909026005A patent/GB9026005D0/en active Pending
1991
- 1991-11-28 SK SK545-93A patent/SK281095B6/sk not_active IP Right Cessation
- 1991-11-28 PL PL91308211A patent/PL169722B1/pl unknown
- 1991-11-28 WO PCT/GB1991/002108 patent/WO1992009557A1/en not_active Ceased
- 1991-11-28 SG SG1996004594A patent/SG49741A1/en unknown
- 1991-11-28 JP JP50047092A patent/JP3375626B2/ja not_active Expired - Lifetime
- 1991-11-28 CA CA002099586A patent/CA2099586C/en not_active Expired - Lifetime
- 1991-11-28 RU RU93040704A patent/RU2116293C1/ru active
- 1991-11-28 IE IE414691A patent/IE914146A1/en not_active IP Right Cessation
- 1991-11-28 CZ CS931019A patent/CZ282996B6/cs not_active IP Right Cessation
- 1991-11-28 DE DE69122780T patent/DE69122780T2/de not_active Expired - Lifetime
- 1991-11-28 HU HU9301568A patent/HU218205B/hu unknown
- 1991-11-28 EP EP92900167A patent/EP0639176B1/en not_active Expired - Lifetime
- 1991-11-28 PL PL91299352A patent/PL167976B1/pl unknown
- 1991-11-28 ZA ZA919401A patent/ZA919401B/xx unknown
- 1991-11-28 ES ES92900167T patent/ES2093812T3/es not_active Expired - Lifetime
- 1991-11-28 AT AT92900167T patent/ATE144244T1/de not_active IP Right Cessation
- 1991-11-28 DK DK92900167.5T patent/DK0639176T3/da active
- 1991-11-28 RU RU97121416/04A patent/RU2197475C2/ru active
- 1991-11-28 AU AU90402/91A patent/AU644505B2/en not_active Ceased
1992
- 1992-05-21 EP EP92304635A patent/EP0571669B1/en not_active Expired - Lifetime
- 1992-05-29 TW TW081104199A patent/TW309425B/zh active
1993
- 1993-05-14 OA OA60370A patent/OA09861A/en unknown
- 1993-05-14 US US08/050,298 patent/US5380922A/en not_active Expired - Lifetime
- 1993-05-25 BG BG97767A patent/BG61340B1/bg unknown
- 1993-05-27 KR KR1019930701589A patent/KR100192196B1/ko not_active Expired - Lifetime
- 1993-05-27 FI FI932422A patent/FI118155B/fi not_active IP Right Cessation
- 1993-09-24 OA OA60416A patent/OA10024A/en unknown
1996
- 1996-12-18 GR GR960403534T patent/GR3022088T3/el unknown
1997
- 1997-06-12 HK HK78997A patent/HK78997A/en not_active IP Right Cessation
1998
- 1998-02-20 CY CY200998A patent/CY2009A/xx unknown
- 1998-09-28 FI FI982081A patent/FI118203B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69122780T2 (de)	1997-02-20
EP0571669A1 (en)	1993-12-01
CA2099586A1 (en)	1992-05-30
AU9040291A (en)	1992-06-25
WO1992009557A1 (en)	1992-06-11
EP0639176B1 (en)	1996-10-16
FI982081L (fi)	1998-09-28
KR100192196B1 (en)	1999-06-15
FI932422A0 (fi)	1993-05-27
FI118203B (fi)	2007-08-31
GR3022088T3 (en)	1997-03-31
JP3375626B2 (ja)	2003-02-10
PL169722B1 (pl)	1996-08-30
FI118155B (fi)	2007-07-31
EP0571669B1 (en)	1996-03-06
GB9026005D0 (en)	1991-01-16
HU218205B (hu)	2000-06-28
HK78997A (en)	1997-06-20
BG61340B1 (en)	1997-06-30
DE69122780D1 (de)	1996-11-21
CZ101993A3 (en)	1994-01-19
ES2093812T3 (es)	1997-01-01
JPH06503082A (ja)	1994-04-07
IE914146A1 (en)	1992-06-03
OA10024A (en)	1996-10-14
SK54593A3 (en)	1993-10-06
ATE144244T1 (de)	1996-11-15
AU644505B2 (en)	1993-12-09
HU9301568D0 (en)	1993-09-28
RU2116293C1 (ru)	1998-07-27
CA2099586C (en)	2002-06-25
TW309425B (cs)	1997-07-01
FI932422L (fi)	1993-05-27
BG97767A (bg)	1994-12-02
HUT64219A (en)	1993-12-28
CY2009A (en)	1998-02-20
SG49741A1 (en)	1998-06-15
PL167976B1 (pl)	1995-12-30
RU2197475C2 (ru)	2003-01-27
EP0639176A1 (en)	1995-02-22
OA09861A (en)	1994-08-15
DK0639176T3 (da)	1996-12-23
FI982081A0 (fi)	1998-09-28
ZA919401B (en)	1992-07-29
US5380922A (en)	1995-01-10
CZ282996B6 (cs)	1997-12-17

Legal Events

Date	Code	Title	Description
2012-01-04	MK4A	Patent expired	Expiry date: 20111128

Publication	Publication Date	Title
DE69625589T2 (de)	2003-09-25	Verfahren zur herstellung einatembarer partikel
WO1991011179A1 (en)	1991-08-08	Aerosol carriers
NL8204013A (nl)	1983-05-16	Steroid en farmaceutisch preparaat alsmede werkwijze voor het bereiden daarvan.
SK95899A3 (en)	2000-01-18	New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
KR102163368B1 (ko)	2020-10-08	플루티카손 프로피오네이트 형태 1의 제조 방법
BR112021008732A2 (pt)	2021-08-03	ingredientes farmacêuticos amorfos ativos compreendendo carbonato de magnésio mesoporoso substancialmente amorfo
SK54593A3 (en)	1993-10-06	Benzenedimethanol suitable for micronisation
Westmeier et al.	2008	Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment
US20040247689A1 (en)	2004-12-09	Process for preparing a pharmaceutical active ingredient with high specific surface area
CN112972384B (zh)	2022-03-18	一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
TWI904746B (zh)	2025-11-11	具有改良溶解度之新穎瓦莫洛龍(vamorolone)製劑
AP323A (en)	1994-03-07	Drug material suitable for micronisation.
SI9200252A (sl)	1994-09-30	Zdravilni material, primeren za mikronizacijo
EP2127641A1 (en)	2009-12-02	Micronisable form of salmeterol xinafoate
WO1993016031A1 (en)	1993-08-19	Benzenedimethanol derivative suitable for micronisation
WO2025032259A1 (en)	2025-02-13	Crystalline compositions
IL101798A (en)	1996-10-16	1-hydroxy-2-naphthalene carboxylate (hydroxynaphthoate) salt of 4-hydroxy- alpha1-[[[6-4-phenylbutoxy) hexyl] amino] methyl]-1,3-benzenedimethanol suitable for micronisation
CZ414899A3 (cs)	2000-02-16	Kompozice obsahující jemně rozptýlené, krystalické částice budesonidu
NZ240788A (en)	1994-02-25	1-hydroxy-2-naphthalene carboxylate salt of 4-hydroxy- alpha 1